메뉴 건너뛰기




Volumn 67, Issue 12, 2007, Pages 1703-1723

Infliximab therapy in children and adolescents with inflammatory bowel disease

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; CERTOLIZUMAB PEGOL; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; MERCAPTOPURINE; METALLOPROTEINASE; ONERCEPT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

EID: 34547923651     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767120-00005     Document Type: Review
Times cited : (34)

References (139)
  • 1
    • 0035656221 scopus 로고    scopus 로고
    • Dysregulation of intestinal mucosal immunity: Implications in inflammatory bowel disease
    • Laroux FS, Pavlick KP, Wolf RE, et al. Dysregulation of intestinal mucosal immunity: implications in inflammatory bowel disease. News Physiol Sci 2001; 16: 272-7
    • (2001) News Physiol Sci , vol.16 , pp. 272-277
    • Laroux, F.S.1    Pavlick, K.P.2    Wolf, R.E.3
  • 2
    • 0242330303 scopus 로고    scopus 로고
    • Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: A statewide population-based study
    • Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr 2003; 143: 525-31
    • (2003) J Pediatr , vol.143 , pp. 525-531
    • Kugathasan, S.1    Judd, R.H.2    Hoffmann, R.G.3
  • 3
    • 0141534418 scopus 로고    scopus 로고
    • Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001
    • Hildebrand H, Finkel Y, Grahnquist L, et al. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut 2003; 52: 1432-4
    • (2003) Gut , vol.52 , pp. 1432-1434
    • Hildebrand, H.1    Finkel, Y.2    Grahnquist, L.3
  • 4
    • 0034080053 scopus 로고    scopus 로고
    • Inflammatory bowel disease in children and adolescents in Sweden, 1984-1995
    • Lindberg E, Lindquist B, Holmquist L, et al. Inflammatory bowel disease in children and adolescents in Sweden, 1984-1995. J Pediatr Gastroenterol Nutr 2000; 30: 259-64
    • (2000) J Pediatr Gastroenterol Nutr , vol.30 , pp. 259-264
    • Lindberg, E.1    Lindquist, B.2    Holmquist, L.3
  • 5
    • 0027164338 scopus 로고
    • Growth and clinical course of children with Crohn's disease
    • Griffiths AM, Nguyen P, Smith C, et al. Growth and clinical course of children with Crohn's disease. Gut 1993; 34: 939-43
    • (1993) Gut , vol.34 , pp. 939-943
    • Griffiths, A.M.1    Nguyen, P.2    Smith, C.3
  • 6
    • 0344946236 scopus 로고    scopus 로고
    • Presenting features of inflammatory bowel disease in Great Britain and Ireland
    • Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child 2003; 88: 995-1000
    • (2003) Arch Dis Child , vol.88 , pp. 995-1000
    • Sawczenko, A.1    Sandhu, B.K.2
  • 7
    • 33745023161 scopus 로고    scopus 로고
    • Inflammatory bowel disease in children: A pediatrician's perspective
    • Cuffari C. Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr 2006; 58: 139-57
    • (2006) Minerva Pediatr , vol.58 , pp. 139-157
    • Cuffari, C.1
  • 8
    • 22044445381 scopus 로고    scopus 로고
    • Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: Recommendations for diagnosis -the Porto criteria
    • IBD Working Group of the European Society for Paediatric Gastroenterology
    • IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis -the Porto criteria. J Pediatr Gastroenterol Nutr 2005; 41: 1-7
    • (2005) J Pediatr Gastroenterol Nutr , vol.41 , pp. 1-7
  • 9
    • 0033770169 scopus 로고    scopus 로고
    • A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease
    • Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn disease. Gastroenterology 2000; 119: 895-902
    • (2000) Gastroenterology , vol.119 , pp. 895-902
    • Markowitz, J.1    Grancher, K.2    Kohn, N.3
  • 10
    • 0034800239 scopus 로고    scopus 로고
    • Surpassing conventional therapies: The role of biologic therapy
    • Baldassano RN. Surpassing conventional therapies: the role of biologic therapy. J Pediatr Gastroenterol Nutr 2001; 33 Suppl. 1: S19-26
    • (2001) J Pediatr Gastroenterol Nutr , vol.33 , Issue.SUPPL. 1
    • Baldassano, R.N.1
  • 11
    • 33644877046 scopus 로고    scopus 로고
    • Early or late guided missile in the treatment of Crohn disease?
    • Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn disease? Dig Liver Dis 2005; 37: 973-9
    • (2005) Dig Liver Dis , vol.37 , pp. 973-979
    • Caprilli, R.1    Angelucci, E.2    Cocco, A.3
  • 12
    • 4544313645 scopus 로고    scopus 로고
    • Managing immunogenic responses to infliximab: Treatment implications for patients with Crohn disease
    • Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn disease. Drugs 2004; 64: 1767-77
    • (2004) Drugs , vol.64 , pp. 1767-1777
    • Han, P.D.1    Cohen, R.D.2
  • 13
    • 33644892470 scopus 로고    scopus 로고
    • Infliximab therapy for inflammatory bowel disease: Seven years on
    • Rutgeerts P, Van Assche G, Vermeire S. Infliximab therapy for inflammatory bowel disease: seven years on. Aliment Pharmacol Ther 2006; 23: 451-63
    • (2006) Aliment Pharmacol Ther , vol.23 , pp. 451-463
    • Rutgeerts, P.1    Van Assche, G.2    Vermeire, S.3
  • 15
    • 33749443342 scopus 로고    scopus 로고
    • A randomized, multicenter, open-label study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate-to-severe Crohn's disease [abstract]
    • Hyams J, Crandall W, Kugathasan S, et al. A randomized, multicenter, open-label study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate-to-severe Crohn's disease [abstract]. J Pediatr Gastroenterol Nutr 2005; 41: 539
    • (2005) J Pediatr Gastroenterol Nutr , vol.41 , pp. 539
    • Hyams, J.1    Crandall, W.2    Kugathasan, S.3
  • 16
    • 0036288520 scopus 로고    scopus 로고
    • Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease
    • Brynskov J, Foegh P, Pedersen G, et al. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002; 51: 37-43
    • (2002) Gut , vol.51 , pp. 37-43
    • Brynskov, J.1    Foegh, P.2    Pedersen, G.3
  • 17
    • 0034020230 scopus 로고    scopus 로고
    • The importance of shedding of membrane proteins for cytokine biology
    • Mullberg J, Althoff K, Jostock T, et al. The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw 2000; 11: 27-38
    • (2000) Eur Cytokine Netw , vol.11 , pp. 27-38
    • Mullberg, J.1    Althoff, K.2    Jostock, T.3
  • 18
    • 0034075936 scopus 로고    scopus 로고
    • Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease
    • Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000; 120: 241-6
    • (2000) Clin Exp Immunol , vol.120 , pp. 241-246
    • Louis, E.1    Ribbens, C.2    Godon, A.3
  • 19
    • 0028236232 scopus 로고
    • Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease
    • Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-66
    • (1994) Gastroenterology , vol.106 , pp. 1455-1466
    • Breese, E.J.1    Michie, C.A.2    Nicholls, S.W.3
  • 20
    • 0027186553 scopus 로고
    • Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea
    • Nicholls S, Stephens S, Braegger CP, et al. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 1993; 46: 757-60
    • (1993) J Clin Pathol , vol.46 , pp. 757-760
    • Nicholls, S.1    Stephens, S.2    Braegger, C.P.3
  • 21
    • 0036840888 scopus 로고    scopus 로고
    • Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytopheresis
    • Tsukada Y, Nakamura T, Iimura M, et al. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytopheresis. Am J Gastroenterol 2002; 97: 2820-8
    • (2002) Am J Gastroenterol , vol.97 , pp. 2820-2828
    • Tsukada, Y.1    Nakamura, T.2    Iimura, M.3
  • 22
    • 0036457057 scopus 로고    scopus 로고
    • Inflammatory bowel disease: New insights into pathogenesis and therapy
    • Ardizzone S, Porro G. Inflammatory bowel disease: new insights into pathogenesis and therapy. J Intern Med 2002; 252: 475-96
    • (2002) J Intern Med , vol.252 , pp. 475-496
    • Ardizzone, S.1    Porro, G.2
  • 23
    • 17744373658 scopus 로고    scopus 로고
    • Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn disease
    • Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn disease. Aliment Pharmacol Ther 2001; 15: 463-73
    • (2001) Aliment Pharmacol Ther , vol.15 , pp. 463-473
    • Cornillie, F.1    Shealy, D.2    D'Haens, G.3
  • 24
    • 2442560241 scopus 로고    scopus 로고
    • Optimizing anti-TNF treatment in inflammatory bowel disease
    • Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610
    • (2004) Gastroenterology , vol.126 , pp. 1593-1610
    • Rutgeerts, P.1    Van Assche, G.2    Vermeire, S.3
  • 25
    • 27644566447 scopus 로고    scopus 로고
    • Biologic therapy for inflammatory bowel disease
    • Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 2253-86
    • (2005) Drugs , vol.65 , pp. 2253-2286
    • Ardizzone, S.1    Bianchi Porro, G.2
  • 26
    • 4344700784 scopus 로고    scopus 로고
    • Downregulation of epithelial apoptosis and barrier repair in active Crohn disease by tumour necrosis factor-alpha antibody treatment
    • Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn disease by tumour necrosis factor-alpha antibody treatment Gut 2004; 53: 1295-1302
    • (2004) Gut , vol.53 , pp. 1295-1302
    • Zeissig, S.1    Bojarski, C.2    Buergel, N.3
  • 27
    • 33744546642 scopus 로고    scopus 로고
    • Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions
    • Begue B, Wajant H, Bambou JC, et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006; 130: 1962-74
    • (2006) Gastroenterology , vol.130 , pp. 1962-1974
    • Begue, B.1    Wajant, H.2    Bambou, J.C.3
  • 28
    • 0038047689 scopus 로고    scopus 로고
    • Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn disease
    • Van den Brande JM, Braat H, van den Brink GP, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn disease. Gastroenterology 2003; 124: 1774-85
    • (2003) Gastroenterology , vol.124 , pp. 1774-1785
    • Van den Brande, J.M.1    Braat, H.2    van den Brink, G.P.3
  • 29
    • 0346461662 scopus 로고    scopus 로고
    • Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn disease
    • Di Sabatino A, Ciccocioppo R, Cinque B, et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn disease. Gut 2004; 53: 70-7
    • (2004) Gut , vol.53 , pp. 70-77
    • Di Sabatino, A.1    Ciccocioppo, R.2    Cinque, B.3
  • 30
    • 0035053968 scopus 로고    scopus 로고
    • An engineered human antibody to TNF (CDP571) for active Crohn disease: A randomized double-bind, placebo-controlled trial
    • Sandborn WJ, Feagen BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn disease: a randomized double-bind, placebo-controlled trial. Gastroenterology 2001; 120: 1330-8
    • (2001) Gastroenterology , vol.120 , pp. 1330-1338
    • Sandborn, W.J.1    Feagen, B.G.2    Hanauer, S.B.3
  • 31
    • 9144261186 scopus 로고    scopus 로고
    • CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease
    • Mamula P, Cohen SA, Ferry GD, et al. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 2004; 10: 723-30
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 723-730
    • Mamula, P.1    Cohen, S.A.2    Ferry, G.D.3
  • 32
    • 0033778364 scopus 로고    scopus 로고
    • Tumor necrosis factor: Biology and therapeutic inhibitors
    • Papadakis CA, Targan SA. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-57
    • (2000) Gastroenterology , vol.119 , pp. 1148-1157
    • Papadakis, C.A.1    Targan, S.A.2
  • 33
    • 14044252848 scopus 로고    scopus 로고
    • Infliximab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept
    • Shen C, Maerten P, Geboes K, et al. Infliximab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005; 21: 251-8
    • (2005) Aliment Pharmacol Ther , vol.21 , pp. 251-258
    • Shen, C.1    Maerten, P.2    Geboes, K.3
  • 34
    • 19144369300 scopus 로고    scopus 로고
    • Adalimumab induces apoptosis of human monocytes and T lymphocytes in a human-mouse chimeric model
    • Shen C, Van Assche G, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005; 115: 250-9
    • (2005) Clin Immunol , vol.115 , pp. 250-259
    • Shen, C.1    Van Assche, G.2    Colpaert, S.3
  • 35
    • 32044474228 scopus 로고    scopus 로고
    • TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: A novel anti-inflammatory mechanism of infliximab in Crohn disease
    • Danese S, Sans M, Scaldaferri F, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn disease. J Immunol 2006; 176: 2617-24
    • (2006) J Immunol , vol.176 , pp. 2617-2624
    • Danese, S.1    Sans, M.2    Scaldaferri, F.3
  • 36
    • 0036678630 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor treatment restores the gut barrier in Crohn disease
    • Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn disease. Am J Gastroenterol 2002; 97: 2007-11
    • (2002) Am J Gastroenterol , vol.97 , pp. 2007-2011
    • Suenaert, P.1    Bulteel, V.2    Lemmens, L.3
  • 37
    • 0027231774 scopus 로고
    • Tumour-necrosis-factor antibody treatment in Crohn disease
    • Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn disease. Lancet 1993; 342: 173-4
    • (1993) Lancet , vol.342 , pp. 173-174
    • Derkx, B.1    Taminiau, J.2    Radema, S.3
  • 38
    • 0030954732 scopus 로고    scopus 로고
    • A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn disease. Crohn Disease cA2 Study Group
    • Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn disease. Crohn Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35
    • (1997) N Engl J Med , vol.337 , pp. 1029-1035
    • Targan, S.R.1    Hanauer, S.B.2    van Deventer, S.J.3
  • 39
    • 0037018761 scopus 로고    scopus 로고
    • Maintenance infliximab for Crohn disease: The ACCENT I randomized trial
    • Hanauer SB, Feagen BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn disease: the ACCENT I randomized trial. Lancet 2002; 359: 1541-9
    • (2002) Lancet , vol.359 , pp. 1541-1549
    • Hanauer, S.B.1    Feagen, B.G.2    Lichtenstein, G.R.3
  • 40
    • 10744224387 scopus 로고    scopus 로고
    • Comparison of scheduled and episodic treatment strategies of infliximab in Crohn disease
    • Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn disease. Gastroenterology 2004; 126: 402-13
    • (2004) Gastroenterology , vol.126 , pp. 402-413
    • Rutgeerts, P.1    Feagan, B.G.2    Lichtenstein, G.R.3
  • 41
    • 0038184193 scopus 로고    scopus 로고
    • Infliximab (REMICADE) therapy in the treatment of pediatric Crohn disease
    • Baldassano RN, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn disease. Am J Gastroenterol 2003; 98: 833-8
    • (2003) Am J Gastroenterol , vol.98 , pp. 833-838
    • Baldassano, R.N.1    Braegger, C.P.2    Escher, J.C.3
  • 42
    • 0033761188 scopus 로고    scopus 로고
    • Prolonged duration of response to infliximab in early but not late pediatric Crohn disease
    • Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn disease. Am J Gastroenterol 2000; 95: 3189-94
    • (2000) Am J Gastroenterol , vol.95 , pp. 3189-3194
    • Kugathasan, S.1    Werlin, S.L.2    Martinez, A.3
  • 43
    • 0034785611 scopus 로고    scopus 로고
    • Prolonged duration of response to infliximab in early pediatric Crohn disease
    • Kugathasan S. Prolonged duration of response to infliximab in early pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2001; 33 Suppl. 1: S40-3
    • (2001) J Pediatr Gastroenterol Nutr , vol.33 , Issue.SUPPL. 1
    • Kugathasan, S.1
  • 44
    • 0033842357 scopus 로고    scopus 로고
    • Use of infliximab in the treatment of Crohn disease in children and adolescents
    • Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn disease in children and adolescents. J Pediatr 2000; 137: 192-6
    • (2000) J Pediatr , vol.137 , pp. 192-196
    • Hyams, J.S.1    Markowitz, J.2    Wyllie, R.3
  • 45
    • 0141613187 scopus 로고    scopus 로고
    • A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease
    • Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (Remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003; 36: 632-6
    • (2003) J Pediatr Gastroenterol Nutr , vol.36 , pp. 632-636
    • Cezard, J.P.1    Nouaili, N.2    Talbotec, C.3
  • 46
    • 4544305960 scopus 로고    scopus 로고
    • Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn disease
    • Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn disease. Dig Liver Dis 2004; 36: 342-7
    • (2004) Dig Liver Dis , vol.36 , pp. 342-347
    • Borrelli, O.1    Bascietto, C.2    Viola, F.3
  • 47
    • 3543101018 scopus 로고    scopus 로고
    • Infliximab therapy in pediatric Crohn's pouchitis
    • Kooros K, Katz AJ. Infliximab therapy in pediatric Crohn's pouchitis. Inflamm Bowel Dis 2004; 10: 417-20
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 417-420
    • Kooros, K.1    Katz, A.J.2
  • 48
    • 0032833517 scopus 로고    scopus 로고
    • Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn disease
    • Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn disease. Gastroenterology 1999; 117: 761-9
    • (1999) Gastroenterology , vol.117 , pp. 761-769
    • Rutgeerts, P.1    D'Haens, G.2    Targan, S.3
  • 49
    • 14644440656 scopus 로고    scopus 로고
    • Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands
    • de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39: 46-52
    • (2004) J Pediatr Gastroenterol Nutr , vol.39 , pp. 46-52
    • de Ridder, L.1    Escher, J.C.2    Bouquet, J.3
  • 50
    • 16544374044 scopus 로고    scopus 로고
    • Infliximab: How to use it in pediatric Crohn disease
    • Ruemmele FM. Infliximab: how to use it in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2004; 39: 12-4
    • (2004) J Pediatr Gastroenterol Nutr , vol.39 , pp. 12-14
    • Ruemmele, F.M.1
  • 51
    • 0042329252 scopus 로고    scopus 로고
    • Response to infliximab is related to disease duration in paediatric Crohn disease
    • Lionetti P, Bronzini F, Salvestrini C. Response to infliximab is related to disease duration in paediatric Crohn disease. Aliment Pharmacol Ther 2003; 18: 425-31
    • (2003) Aliment Pharmacol Ther , vol.18 , pp. 425-431
    • Lionetti, P.1    Bronzini, F.2    Salvestrini, C.3
  • 52
    • 9144234882 scopus 로고    scopus 로고
    • Efficacy and tolerance of infliximab in children and adolescents with Crohn disease
    • Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn disease. Inflamm Bowel Dis 2004; 10: 745-50
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 745-750
    • Lamireau, T.1    Cezard, J.P.2    Dabadie, A.3
  • 53
    • 30344431805 scopus 로고    scopus 로고
    • Infliximab dependency in a national cohort of children with Crohn disease
    • Wewer V, Riis L, Vind I, et al. Infliximab dependency in a national cohort of children with Crohn disease. J Pediatr Gastroenterol Nutr 2006; 42: 40-5
    • (2006) J Pediatr Gastroenterol Nutr , vol.42 , pp. 40-45
    • Wewer, V.1    Riis, L.2    Vind, I.3
  • 54
    • 29444445950 scopus 로고    scopus 로고
    • Clinical and biological consequences of immunization to infliximab in pediatric Crohn disease
    • Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn disease. Clin Immunol 2006; 118: 11-9
    • (2006) Clin Immunol , vol.118 , pp. 11-19
    • Candon, S.1    Mosca, A.2    Ruemmele, F.3
  • 55
    • 0033529049 scopus 로고    scopus 로고
    • Infliximab for the treatment of fistulas in patients with Crohn disease
    • Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn disease. N Engl J Med 1999; 340: 1398-405
    • (1999) N Engl J Med , vol.340 , pp. 1398-1405
    • Present, D.H.1    Rutgeerts, P.2    Targan, S.3
  • 56
    • 10744221312 scopus 로고    scopus 로고
    • Infliximab maintenance therapy for fistulizing Crohn disease
    • Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn disease. N Engl J Med 2004; 350: 876-85
    • (2004) N Engl J Med , vol.350 , pp. 876-885
    • Sands, B.E.1    Anderson, F.H.2    Bernstein, C.N.3
  • 57
    • 17144388945 scopus 로고    scopus 로고
    • Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn disease
    • Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn disease. Gastroenterology 2005; 128: 862-9
    • (2005) Gastroenterology , vol.128 , pp. 862-869
    • Lichtenstein, G.R.1    Yan, S.2    Bala, M.3
  • 58
    • 33646883499 scopus 로고    scopus 로고
    • Maintenance infliximab does not result in increased abscess development in fistulizing Crohn disease: Results from the ACCENT II study
    • Sands BE, Blank MA, Diamond RH, et al. Maintenance infliximab does not result in increased abscess development in fistulizing Crohn disease: results from the ACCENT II study. Aliment Pharmacol Ther 2006; 23: 1127-36
    • (2006) Aliment Pharmacol Ther , vol.23 , pp. 1127-1136
    • Sands, B.E.1    Blank, M.A.2    Diamond, R.H.3
  • 59
    • 5044235159 scopus 로고    scopus 로고
    • Long-term treatment of rectovaginal fistulas in Crohn disease: Response to infliximab in the ACCENT II Study
    • Sands BE, Blank MA, Patel K, et al. Long-term treatment of rectovaginal fistulas in Crohn disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-20
    • (2004) Clin Gastroenterol Hepatol , vol.2 , pp. 912-920
    • Sands, B.E.1    Blank, M.A.2    Patel, K.3
  • 60
    • 9144268929 scopus 로고    scopus 로고
    • Infliximab: Lack of efficacy on perforating complications in Crohn disease
    • Miehsler W, Reinisch W, Kazemi-Shirazi L, et al. Infliximab: lack of efficacy on perforating complications in Crohn disease. Inflamm Bowel Dis 2004; 10: 36-40
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 36-40
    • Miehsler, W.1    Reinisch, W.2    Kazemi-Shirazi, L.3
  • 61
    • 33748675696 scopus 로고    scopus 로고
    • Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: A pilot study
    • Asteria CR, Ficari F, Bagnoli S, et al. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol 2006; 41: 1064-72
    • (2006) Scand J Gastroenterol , vol.41 , pp. 1064-1072
    • Asteria, C.R.1    Ficari, F.2    Bagnoli, S.3
  • 62
  • 63
    • 33644921817 scopus 로고    scopus 로고
    • A case of refractory pediatric Crohn disease with a successful treatment by infliximab therapy
    • Park SH, Jeen YT, Chun HR, et al. A case of refractory pediatric Crohn disease with a successful treatment by infliximab therapy. Korean J Gastroenterol 2005; 46: 297-301
    • (2005) Korean J Gastroenterol , vol.46 , pp. 297-301
    • Park, S.H.1    Jeen, Y.T.2    Chun, H.R.3
  • 64
    • 33846635983 scopus 로고    scopus 로고
    • Infliximab in pediatric Crohn disease patients with enterovesicular fistulas
    • Teitelbaum JE, Saeed S, Triantafyllopoulou M, et al. Infliximab in pediatric Crohn disease patients with enterovesicular fistulas. J Ped Gastroent Nutr 2007; 44: 279-82
    • (2007) J Ped Gastroent Nutr , vol.44 , pp. 279-282
    • Teitelbaum, J.E.1    Saeed, S.2    Triantafyllopoulou, M.3
  • 65
    • 0037282938 scopus 로고    scopus 로고
    • Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn disease
    • Van Assche G, Vanbeckevoort D, Bielen D, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn disease. Am J Gastroenterol 2003; 98: 332-9
    • (2003) Am J Gastroenterol , vol.98 , pp. 332-339
    • Van Assche, G.1    Vanbeckevoort, D.2    Bielen, D.3
  • 66
    • 0037325450 scopus 로고    scopus 로고
    • Response of fistulizing Crohn disease to infliximab treatment assessed by magnetic resonance imaging
    • Bell SJ, Halligan S, Windsor AC, et al. Response of fistulizing Crohn disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2003; 17: 387-93
    • (2003) Aliment Pharmacol Ther , vol.17 , pp. 387-393
    • Bell, S.J.1    Halligan, S.2    Windsor, A.C.3
  • 67
    • 0037348380 scopus 로고    scopus 로고
    • Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement
    • Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9: 98-103
    • (2003) Inflamm Bowel Dis , vol.9 , pp. 98-103
    • Regueiro, M.1    Mardini, H.2
  • 68
    • 0034777502 scopus 로고    scopus 로고
    • Infliximab in the treatment of severe, corticosteroid-refractory ulcerative colitis: A pilot study
    • Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, corticosteroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001; 7: 83-8
    • (2001) Inflamm Bowel Dis , vol.7 , pp. 83-88
    • Sands, B.E.1    Tremaine, W.J.2    Sandborn, W.J.3
  • 69
    • 0038460945 scopus 로고    scopus 로고
    • Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial
    • Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003; 52: 998-1002
    • (2003) Gut , vol.52 , pp. 998-1002
    • Probert, C.S.1    Hearing, S.D.2    Schreiber, S.3
  • 70
    • 8444238193 scopus 로고    scopus 로고
    • Infliximab for acute, not corticosteroid-refractory ulcerative colitis: A randomized pilot study
    • Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not corticosteroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004; 16: 1167-71
    • (2004) Eur J Gastroenterol Hepatol , vol.16 , pp. 1167-1171
    • Ochsenkuhn, T.1    Sackmann, M.2    Goke, B.3
  • 71
    • 27644549042 scopus 로고    scopus 로고
    • State of the art: IBD therapy and clinical trials in IBD
    • Isaacs KL, Lewis JD, Sandborn WJ, et al. State of the art: IBD therapy and clinical trials in IBD. Inflamm Bowel Dis 2005; 11 Suppl. 1: S3-12
    • (2005) Inflamm Bowel Dis , vol.11 , Issue.SUPPL. 1
    • Isaacs, K.L.1    Lewis, J.D.2    Sandborn, W.J.3
  • 72
    • 28844473957 scopus 로고    scopus 로고
    • Infliximab for induction and maintenance therapy for ulcerative colitis
    • Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-76
    • (2005) N Engl J Med , vol.353 , pp. 2462-2476
    • Rutgeerts, P.1    Sandborn, W.J.2    Feagan, B.G.3
  • 73
    • 20444479336 scopus 로고    scopus 로고
    • Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebo-controlled study
    • Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11
    • (2005) Gastroenterology , vol.128 , pp. 1805-1811
    • Jarnerot, G.1    Hertervig, E.2    Friis-Liby, I.3
  • 74
    • 33750105599 scopus 로고    scopus 로고
    • Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis
    • CD005112
    • Lawson M, Thomas A, Akobeng A. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006; (3): CD005112
    • (2006) Cochrane Database Syst Rev , Issue.3
    • Lawson, M.1    Thomas, A.2    Akobeng, A.3
  • 75
  • 76
  • 77
    • 15944366494 scopus 로고    scopus 로고
    • Infliximab efficacy in pediatric ulcerative colitis
    • Eidelwein AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005; 11: 213-8
    • (2005) Inflamm Bowel Dis , vol.11 , pp. 213-218
    • Eidelwein, A.P.1    Cuffari, C.2    Abadom, V.3
  • 78
    • 0034911830 scopus 로고    scopus 로고
    • Use of infliximab in pediatric patients with inflammatory bowel disease
    • Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, et al. Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 2001; 35: 823-8
    • (2001) Ann Pharmacother , vol.35 , pp. 823-828
    • Serrano, M.S.1    Schmidt-Sommerfeld, E.2    Kilbaugh, T.J.3
  • 79
    • 0010612959 scopus 로고    scopus 로고
    • Infliximab therapy for pediatric ulcerative colitis [abstract]
    • Oliva-Hemker M, Roper S, Cuffari C, et al. Infliximab therapy for pediatric ulcerative colitis [abstract]. Gastroenterology 2002; 122: A616
    • (2002) Gastroenterology , vol.122
    • Oliva-Hemker, M.1    Roper, S.2    Cuffari, C.3
  • 80
    • 33847700853 scopus 로고    scopus 로고
    • Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis
    • Fanjiang G, Russell GH. Katz AJ. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2007; 44: 312-7
    • (2007) J Pediatr Gastroenterol Nutr , vol.44 , pp. 312-317
    • Fanjiang, G.1    Russell, G.H.2    Katz, A.J.3
  • 81
    • 0028292007 scopus 로고
    • Cyclosporine in severe ulcerative colitis refractory to steroid therapy
    • Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New Engl J Med 1994; 330: 1841-5
    • (1994) New Engl J Med , vol.330 , pp. 1841-1845
    • Lichtiger, S.1    Present, D.H.2    Kornbluth, A.3
  • 82
    • 33847709966 scopus 로고    scopus 로고
    • Anti-tumour necrosis factor therapy for ulcerative colitis: Evidence to date
    • Thukral C, Cheifetz A, Peppercorn MA. Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date. Drugs 2006; 66: 2059-65
    • (2006) Drugs , vol.66 , pp. 2059-2065
    • Thukral, C.1    Cheifetz, A.2    Peppercorn, M.A.3
  • 83
    • 0142091279 scopus 로고    scopus 로고
    • Infliximab in the treatment of medically refractory indeterminate colitis
    • Papadakis KA, Treyzon L, Abreu MT, et al. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther 2003; 18: 741-7
    • (2003) Aliment Pharmacol Ther , vol.18 , pp. 741-747
    • Papadakis, K.A.1    Treyzon, L.2    Abreu, M.T.3
  • 84
    • 0042128405 scopus 로고    scopus 로고
    • Infliximab for refractory ulcerative colitis or indeterminate colitis: An open-label multicentre study
    • Gornet JM, Couve S, Hassani Z, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003; 18: 175-81
    • (2003) Aliment Pharmacol Ther , vol.18 , pp. 175-181
    • Gornet, J.M.1    Couve, S.2    Hassani, Z.3
  • 85
    • 0041571851 scopus 로고    scopus 로고
    • Infliximab for treatment of Pyoderma gangrenosum associated with inflammatory bowel disease
    • Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1821-6
    • (2003) Am J Gastroenterol , vol.98 , pp. 1821-1826
    • Regueiro, M.1    Valentine, J.2    Plevy, S.3
  • 86
    • 33645128368 scopus 로고    scopus 로고
    • Infliximab for the treatment of Pyoderma gangrenosum: A randomised, double blind, placebo controlled trial
    • Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of Pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-9
    • (2006) Gut , vol.55 , pp. 505-509
    • Brooklyn, T.N.1    Dunnill, M.G.2    Shetty, A.3
  • 87
    • 1542707085 scopus 로고    scopus 로고
    • Dermatologic manifestations of Crohn disease in children: Response to infliximab
    • Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003; 37: 150-4
    • (2003) J Pediatr Gastroenterol Nutr , vol.37 , pp. 150-154
    • Kugathasan, S.1    Miranda, A.2    Nocton, J.3
  • 88
    • 0036259538 scopus 로고    scopus 로고
    • Resolution of severe peristomal Pyoderma gangrenosum with infliximab in a child with Crohn disease
    • Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal Pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr 2002; 34: 558-60
    • (2002) J Pediatr Gastroenterol Nutr , vol.34 , pp. 558-560
    • Batres, L.A.1    Mamula, P.2    Baldassano, R.N.3
  • 89
    • 33750321159 scopus 로고    scopus 로고
    • Uveitis: Advances in understanding of pathogenesis and treatment
    • Read RW. Uveitis: advances in understanding of pathogenesis and treatment. Curr Rheumatol Rep 2006; 8: 260-6
    • (2006) Curr Rheumatol Rep , vol.8 , pp. 260-266
    • Read, R.W.1
  • 90
    • 31644442632 scopus 로고    scopus 로고
    • Retrospective case review of pediatric patients with uveitis treated with infliximab
    • Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 2006; 113: 308-14
    • (2006) Ophthalmology , vol.113 , pp. 308-314
    • Rajaraman, R.T.1    Kimura, Y.2    Li, S.3
  • 91
    • 33745581724 scopus 로고    scopus 로고
    • Juvenile idiopathic arthritis: An update on clinical and therapeutic approaches
    • Quarta L, Corrado A, Melillo N, et al. Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches. Ann Ital Med Int 2005; 20: 211-7
    • (2005) Ann Ital Med Int , vol.20 , pp. 211-217
    • Quarta, L.1    Corrado, A.2    Melillo, N.3
  • 93
    • 33645321124 scopus 로고    scopus 로고
    • Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: Response to infliximab
    • Silbermintz A, Krishnan S, Banquet A, et al. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. J Pediatr Gastroenterol Nutr 2006; 42: 324-6
    • (2006) J Pediatr Gastroenterol Nutr , vol.42 , pp. 324-326
    • Silbermintz, A.1    Krishnan, S.2    Banquet, A.3
  • 94
    • 0037029430 scopus 로고    scopus 로고
    • Treatment of active anky-losing spondylitis with infliximab: A randomised controlled multicentre trial
    • Braun J, Brandt J, Listing J, et al. Treatment of active anky-losing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-93
    • (2002) Lancet , vol.359 , pp. 1187-1193
    • Braun, J.1    Brandt, J.2    Listing, J.3
  • 95
    • 0034715977 scopus 로고    scopus 로고
    • Crohn's disease associated with spondyloarthropathy: Effect of TNF-alpha blockade with infliximab on articular symptoms
    • Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-2
    • (2000) Lancet , vol.356 , pp. 1821-1822
    • Van den Bosch, F.1    Kruithof, E.2    De Vos, M.3
  • 98
    • 29444445452 scopus 로고    scopus 로고
    • Management of recent onset Crohn's Disease: A controlled, randomized trial comparing step-up and top-down therapy [abstract]
    • Hommes D, Baert F, van Assche G, et al. Management of recent onset Crohn's Disease: a controlled, randomized trial comparing step-up and top-down therapy [abstract]. Gastroenterology 2005; 129: 371
    • (2005) Gastroenterology , vol.129 , pp. 371
    • Hommes, D.1    Baert, F.2    van Assche, G.3
  • 99
    • 33747337737 scopus 로고    scopus 로고
    • Biological therapy in the management of recent-onset Crohns disease: Why, when and how?
    • Löwenberg M, Peppelenbosch M, Hommes D. Biological therapy in the management of recent-onset Crohns disease: why, when and how? Drugs 2006; 66: 1431-9
    • (2006) Drugs , vol.66 , pp. 1431-1439
    • Löwenberg, M.1    Peppelenbosch, M.2    Hommes, D.3
  • 100
    • 0037434552 scopus 로고    scopus 로고
    • Influence of immunogenicity on the long-term efficacy of infliximab in Crohn disease
    • Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn disease. N Engl J Med 2003; 348: 601-8
    • (2003) N Engl J Med , vol.348 , pp. 601-608
    • Baert, F.1    Noman, M.2    Vermeire, S.3
  • 101
    • 0037379792 scopus 로고    scopus 로고
    • Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn disease: A randomized controlled trial
    • Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24
    • (2003) Gastroenterology , vol.124 , pp. 917-924
    • Farrell, R.J.1    Alsahli, M.2    Jeen, Y.T.3
  • 102
    • 0038109994 scopus 로고    scopus 로고
    • Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn disease: A prospective cohort study
    • Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn disease: a prospective cohort study. Gastroenterology 2003; 125: 32-9
    • (2003) Gastroenterology , vol.125 , pp. 32-39
    • Vermeire, S.1    Noman, M.2    Van Assche, G.3
  • 103
    • 0038649858 scopus 로고    scopus 로고
    • The incidence and management of infusion reactions to infliximab: A large center experience
    • Cheifetz A, Smedley M, Martin S. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98: 1315-24
    • (2003) Am J Gastroenterol , vol.98 , pp. 1315-1324
    • Cheifetz, A.1    Smedley, M.2    Martin, S.3
  • 104
    • 2342538439 scopus 로고    scopus 로고
    • Infliximab infusion reactions: Desensitizing ourselves to the danger
    • Persley KM. Infliximab infusion reactions: desensitizing ourselves to the danger. Inflamm Bowel Dis 2004; 10: 62-3
    • (2004) Inflamm Bowel Dis , vol.10 , pp. 62-63
    • Persley, K.M.1
  • 105
    • 0037259135 scopus 로고    scopus 로고
    • Safety and corticosteroid-sparing experience using infliximab for Crohn disease at a pediatric inflammatory bowel disease center
    • Stephens MC, Shepanski MA, Mamula P, et al. Safety and corticosteroid-sparing experience using infliximab for Crohn disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol 2003; 98: 104-11
    • (2003) Am J Gastroenterol , vol.98 , pp. 104-111
    • Stephens, M.C.1    Shepanski, M.A.2    Mamula, P.3
  • 106
    • 0035344608 scopus 로고    scopus 로고
    • Efficacy and safety of repeated infliximab infusions for Crohn disease: 1-year clinical experience
    • Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn disease: 1-year clinical experience. Inflamm Bowel Dis 2001; 7 Suppl. 1: S17-22
    • (2001) Inflamm Bowel Dis , vol.7 , Issue.SUPPL. 1
    • Cohen, R.D.1
  • 107
    • 0033634684 scopus 로고    scopus 로고
    • Infliximab in Crohn disease: First anniversary clinical experience
    • Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95: 3469-77
    • (2000) Am J Gastroenterol , vol.95 , pp. 3469-3477
    • Cohen, R.D.1    Tsang, J.F.2    Hanauer, S.B.3
  • 108
    • 3543106683 scopus 로고    scopus 로고
    • Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab
    • Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004; 38: 502-8
    • (2004) J Pediatr Gastroenterol Nutr , vol.38 , pp. 502-508
    • Miele, E.1    Markowitz, J.E.2    Mamula, P.3
  • 109
    • 0036081770 scopus 로고    scopus 로고
    • Infliximab retreatment in adults and children with Crohn disease: Risk factors for the development of delayed severe systemic reaction
    • Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 2002; 97: 1408-14
    • (2002) Am J Gastroenterol , vol.97 , pp. 1408-1414
    • Kugathasan, S.1    Levy, M.B.2    Saeian, K.3
  • 110
    • 33645471164 scopus 로고    scopus 로고
    • What's new: Innovative concepts in inflammatory bowel disease
    • Sandborn WJ. What's new: innovative concepts in inflammatory bowel disease. Colorectal Dis 2006; 8 Suppl. 1: 3-9
    • (2006) Colorectal Dis , vol.8 , Issue.SUPPL. 1 , pp. 3-9
    • Sandborn, W.J.1
  • 111
    • 4344717441 scopus 로고    scopus 로고
    • Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004; 53: 1366-73
    • Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004; 53: 1366-73
  • 112
    • 0037379757 scopus 로고    scopus 로고
    • Preventing antibodies to infliximab in patients with Crohn disease: Optimize not immunize
    • Sandborn WJ. Preventing antibodies to infliximab in patients with Crohn disease: optimize not immunize. Gastroenterology 2003; 124: 1140-5
    • (2003) Gastroenterology , vol.124 , pp. 1140-1145
    • Sandborn, W.J.1
  • 113
    • 18944367848 scopus 로고    scopus 로고
    • Premedication and infusion reactions with infliximab: Results from a pediatric inflammatory bowel disease consortium
    • Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005; 11: 442-6
    • (2005) Inflamm Bowel Dis , vol.11 , pp. 442-446
    • Jacobstein, D.A.1    Markowitz, J.E.2    Kirschner, B.S.3
  • 114
    • 13144265888 scopus 로고    scopus 로고
    • Safety of infliximab treatment in pediatric patients with inflammatory bowel disease
    • Friesen CA, Calabro C, Christenson K, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2004; 39: 265-9
    • (2004) J Pediatr Gastroenterol Nutr , vol.39 , pp. 265-269
    • Friesen, C.A.1    Calabro, C.2    Christenson, K.3
  • 115
    • 0000658017 scopus 로고    scopus 로고
    • Infliximab infusion reactions: The influence of sex and drugs
    • Han PD, Cohen RD, Motamedi F, et al. Infliximab infusion reactions: the influence of sex and drugs. Gastroenterology 2002; 122 Suppl. 4: A612
    • (2002) Gastroenterology , vol.122 , Issue.SUPPL. 4
    • Han, P.D.1    Cohen, R.D.2    Motamedi, F.3
  • 116
    • 22844450941 scopus 로고    scopus 로고
    • A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes
    • Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005; 123: 903-12
    • (2005) Arch Ophthalmol , vol.123 , pp. 903-912
    • Suhler, E.B.1    Smith, J.R.2    Wertheim, M.S.3
  • 117
    • 0242499967 scopus 로고    scopus 로고
    • Development of antinuclear antibodies and its clinical impact in patients with Crohn disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab)
    • Garcia-Planella E, Domenech E, Esteve-Comas M, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol 2003; 15: 351-4
    • (2003) Eur J Gastroenterol Hepatol , vol.15 , pp. 351-354
    • Garcia-Planella, E.1    Domenech, E.2    Esteve-Comas, M.3
  • 118
    • 0037405058 scopus 로고    scopus 로고
    • Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab
    • McIlwain L, Carter JD, Bin-Sagheer S, et al. Hypersensitivity vasculitis with leukocytoclastic vasculitis secondary to infliximab. J Clin Gastroenterol 2003; 36: 411-3
    • (2003) J Clin Gastroenterol , vol.36 , pp. 411-413
    • McIlwain, L.1    Carter, J.D.2    Bin-Sagheer, S.3
  • 119
    • 0037247042 scopus 로고    scopus 로고
    • Infusion reactions to infliximab in children and adolescents: Frequency, outcome and a predictive model
    • Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17: 75-84
    • (2003) Aliment Pharmacol Ther , vol.17 , pp. 75-84
    • Crandall, W.V.1    Mackner, L.M.2
  • 120
    • 0035007087 scopus 로고    scopus 로고
    • Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction
    • Puchner TC, Kugathasan S, Kelly KJ, et al. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm Bowel Dis 2001; 7: 34-7
    • (2001) Inflamm Bowel Dis , vol.7 , pp. 34-37
    • Puchner, T.C.1    Kugathasan, S.2    Kelly, K.J.3
  • 121
    • 0345609037 scopus 로고    scopus 로고
    • Characterization of tumor necrosis factor-deficient mice
    • Marino MW, Dunn A, Grail D, et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A 1997; 94: 8093-8
    • (1997) Proc Natl Acad Sci U S A , vol.94 , pp. 8093-8098
    • Marino, M.W.1    Dunn, A.2    Grail, D.3
  • 122
    • 0347991877 scopus 로고    scopus 로고
    • The safety profile of infliximab in patients with Crohn disease: The Mayo clinic experience in 500 patients
    • Colombel JF, Loftus Jr EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31
    • (2004) Gastroenterology , vol.126 , pp. 19-31
    • Colombel, J.F.1    Loftus Jr, E.V.2    Tremaine, W.J.3
  • 124
    • 24144479466 scopus 로고    scopus 로고
    • Increased risk for demyelinating diseases in patients with inflammatory bowel disease
    • Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129: 819-26
    • (2005) Gastroenterology , vol.129 , pp. 819-826
    • Gupta, G.1    Gelfand, J.M.2    Lewis, J.D.3
  • 125
    • 33644875213 scopus 로고    scopus 로고
    • TNF-alpha inhibitors and congestive heart failure
    • Behnam SM, Behnam SE, Koo JY. TNF-alpha inhibitors and congestive heart failure. Skinmed 2005; 4: 363-8
    • (2005) Skinmed , vol.4 , pp. 363-368
    • Behnam, S.M.1    Behnam, S.E.2    Koo, J.Y.3
  • 126
    • 0036255224 scopus 로고    scopus 로고
    • Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus) after treatment with infliximab in a boy with Crohn disease
    • Reichardt P, Dahnert I, Tiller G, et al. Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus) after treatment with infliximab in a boy with Crohn disease. Eur J Paed 2002; 161: 281-3
    • (2002) Eur J Paed , vol.161 , pp. 281-283
    • Reichardt, P.1    Dahnert, I.2    Tiller, G.3
  • 127
    • 1842833370 scopus 로고    scopus 로고
    • Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis
    • Armbrust W, Kamphuis SS, Wolfs TW, et al. Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology 2004; 43: 527-9
    • (2004) Rheumatology , vol.43 , pp. 527-529
    • Armbrust, W.1    Kamphuis, S.S.2    Wolfs, T.W.3
  • 128
    • 0037148920 scopus 로고    scopus 로고
    • Tuberculosis and treatment with infliximab
    • Myers A, Clark J, Foster H. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346: 623-6
    • (2002) N Engl J Med , vol.346 , pp. 623-626
    • Myers, A.1    Clark, J.2    Foster, H.3
  • 129
    • 0035846326 scopus 로고    scopus 로고
    • Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
    • Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-104
    • (2001) N Engl J Med , vol.345 , pp. 1098-1104
    • Keane, J.1    Gershon, S.2    Wise, R.P.3
  • 130
    • 33750485302 scopus 로고    scopus 로고
    • Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor
    • Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2: 602-10
    • (2006) Nat Clin Pract Rheumatol , vol.2 , pp. 602-610
    • Winthrop, K.L.1
  • 131
    • 1842479974 scopus 로고    scopus 로고
    • High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy
    • Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-13
    • (2004) Clin Gastroenterol Hepatol , vol.2 , pp. 309-313
    • Mow, W.S.1    Abreu-Martin, M.T.2    Papadakis, K.A.3
  • 132
    • 33646147141 scopus 로고    scopus 로고
    • Serious infections and mortality in association with therapies for Crohn disease: TREAT registry
    • Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 621-630
    • Lichtenstein, G.R.1    Feagan, B.G.2    Cohen, R.D.3
  • 133
    • 33646696885 scopus 로고    scopus 로고
    • Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
    • Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-85
    • (2006) JAMA , vol.295 , pp. 2275-2285
    • Bongartz, T.1    Sutton, A.J.2    Sweeting, M.J.3
  • 134
    • 0037344897 scopus 로고    scopus 로고
    • Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine
    • Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003; 44: 531-3
    • (2003) Leuk Lymphoma , vol.44 , pp. 531-533
    • Navarro, J.T.1    Ribera, J.M.2    Mate, J.L.3
  • 135
    • 30944442404 scopus 로고    scopus 로고
    • Infliximab and newly diagnosed neoplasia in Crohn's disease: A multicentre matched pair study
    • Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 2006; 55: 228-33
    • (2006) Gut , vol.55 , pp. 228-233
    • Biancone, L.1    Orlando, A.2    Kohn, A.3
  • 136
    • 33746345358 scopus 로고    scopus 로고
    • Risks and benefits of infliximab for the treatment of Crohn's disease
    • Siegel CA, Hur C, Korzenik JR. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1017-24
    • (2006) Clin Gastroenterol Hepatol , vol.4 , pp. 1017-1024
    • Siegel, C.A.1    Hur, C.2    Korzenik, J.R.3
  • 137
    • 13944252969 scopus 로고    scopus 로고
    • Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease
    • Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005; 40: 220-2
    • (2005) J Pediatr Gastroenterol Nutr , vol.40 , pp. 220-222
    • Thayu, M.1    Markowitz, J.E.2    Mamula, P.3
  • 138
    • 33846592386 scopus 로고    scopus 로고
    • Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease
    • Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-7
    • (2007) J Pediatr Gastroenterol Nutr , vol.44 , pp. 265-267
    • Mackey, A.C.1    Green, L.2    Liang, L.C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.